As the treatment paradigm in inflammatory bowel disease (IBD) has shifted from controlling symptoms to fully controlling disease in order to prevent organ damage and disability, some have argued that disability is a better, more objective measure than quality of life in clinical trials and population studies of IBD.
As the treatment paradigm in inflammatory bowel disease (IBD) has shifted from controlling symptoms to fully controlling disease in order to prevent organ damage and disability, some have argued that disability is a better, more objective measure than quality of life in clinical trials and population studies of IBD.
A November 2017 review in Therapeutic Advances in Gastroenterology by Patrick B. Allen, MD, and colleagues investigated measuring disability in IBD, defined in 2001 by the World Health Organization (WHO) in its International Classification of Functioning, Disability and Health (ICF) as “any restriction or lack (resulting from impairment) of ability to perform an activity in the manner or within the range considered normal for a human being.”
IBD is known to affect physical, psychological, familial, and social dimensions of life; the psychological impact of IBD may also contribute to disability. While experience with rheumatoid arthritis (RA) and multiple sclerosis (MS) has shown that disability can be prevented by disease-modifying drugs, such evidence is currently lacking in IBD. The review points out that WHO’s validated disability index can be used to explore whether disability can also be prevented in IBD.
In 2007 the IBD Disability Index (IBD-DI) was developed in collaboration with WHO and was validated in a French population-based study. The IBD-DI demonstrated high internal consistency, interobserver reliability and construct validity, and moderate intraobserver reliability. The IBD-DI is used mainly in the clinical trial setting because it evaluates functional status. A shortened, self-administered adaptation of the validated IBD-DI known as the IBD Disk was more recently developed to permit immediate visual representation of patient-reported disability markers such as sleep, sexual function, abdominal pain, body image, and energy. The disk lacks validation, but has the potential to be a valuable outcome measure for use during routine clinical visits.
Dr. Allen and colleagues performed a literature search through June 2017 using keywords pertaining to IBD and searched abstracts from the annual meetings of the major gastroenterology groups. Many studies and questionnaires about IBD primarily focused on subjective measures of disease. Fatigue and pain were found to be commonly reported symptoms in patients with IBD. A large proportion of patients were found to require opioid analgesia, and patients with IBD were reported to experience frequent and concomitant anxiety and depression. Overall, disability was found to be high in both Crohn disease and ulcerative colitis and to contribute to disease burden in IBD.
The review concludes that disability is prevalent in IBD and is seen in patients with ulcerative colitis (UC) before and after surgery and in Crohn disease (CD). “The IBD-DI should become a major secondary endpoint in clinical trials,” the review authors state. “This index needs to be expanded to include worldwide comparisons of disability among IBD patients in a longitudinal fashion.”
Future clinical trials will move away from simply targeting response and remission to ensure deep remission, improvement in defined patient-reported outcomes, and ultimately preventing and improving disability in IBD, the review concludes. “The costs and safety of these new therapeutic strategies in IBD that are being developed to change the natural history of disease with earlier and effective treatments in order to reduce long-term disability in IBD patients, remain to be established.”
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.